Polypharmacy & Medication Safety — Drug Interactions, Deprescribing, and High-Risk Medications in Older Adults - USMLE Step 2

SECTION 1

Historical Context & The Rise of Polypharmacy

The concept of polypharmacy — typically defined as the concurrent use of five or more medications — has evolved from a minor clinical concern to one of the most pressing patient safety challenges in modern geriatric medicine. Throughout much of the twentieth century, older adults received relatively few chronic medications, but the advent of evidence-based guidelines for individual diseases such as hypertension, diabetes, heart failure, and osteoporosis led to a dramatic increase in the number of prescriptions per patient. Each guideline, developed largely from trials in younger populations, recommends specific pharmacotherapy, and a patient with multiple comorbidities may accumulate a regimen that no single trial ever tested in combination. The resulting medication burden introduces compounding risks of adverse drug events, drug-drug interactions, nonadherence, and functional decline.

The recognition that more medications do not always translate to better outcomes prompted a paradigm shift toward patient-centered prescribing, wherein the goals, life expectancy, and functional status of the individual patient guide medication decisions rather than disease-specific algorithms alone. This shift has given rise to the fields of deprescribing, medication reconciliation, and the systematic identification of potentially inappropriate medications (PIMs).

1991 • Beers Criteria Published

Mark Beers and colleagues published the first explicit list of potentially inappropriate medications for nursing home residents, establishing a landmark tool for identifying high-risk prescribing in older adults.

2003 • STOPP/START Criteria Emerge

European researchers introduced the Screening Tool of Older Persons' Prescriptions (STOPP) and Screening Tool to Alert to Right Treatment (START), pairing medications to avoid with those that should be initiated.

2012 • Choosing Wisely Campaign

The American Board of Internal Medicine Foundation launched Choosing Wisely, encouraging conversations about unnecessary medications and procedures, further normalizing deprescribing in clinical practice.

2015 • Deprescribing Guidelines Published

Evidence-based deprescribing guidelines for proton pump inhibitors, benzodiazepines, antipsychotics, and other high-risk drug classes were systematically developed and disseminated worldwide.

2023 • Updated AGS Beers Criteria

The American Geriatrics Society released an updated Beers Criteria reflecting new evidence, expanding categories, and emphasizing individualized clinical judgment alongside the explicit criteria.

Despite these advances, polypharmacy remains pervasive: more than 40% of community-dwelling adults aged 65 and older take five or more prescription medications, and the prevalence rises sharply in nursing home populations. The central question this lesson addresses is how clinicians can systematically identify, prevent, and manage inappropriate polypharmacy while maintaining therapies that provide genuine benefit to the individual patient.

SECTION 2

Core Principles of Medication Safety in Older Adults

Medication safety in the geriatric population rests on several interconnected principles that account for the unique pharmacological vulnerabilities of aging. Age-related physiologic changes — reduced renal clearance, diminished hepatic metabolism, increased body fat relative to lean mass, and decreased albumin — all alter the pharmacokinetics and pharmacodynamics of many drugs, increasing the likelihood of toxicity even at standard adult doses. Additionally, the aging brain exhibits heightened sensitivity to centrally acting agents, meaning that drugs with anticholinergic, sedative, or psychoactive properties carry disproportionate risk for falls, delirium, and cognitive impairment in this population.

Altered Pharmacokinetics

Decreased GFR, reduced hepatic blood flow, increased volume of distribution for lipophilic drugs, and decreased plasma protein binding change drug absorption, distribution, metabolism, and excretion profiles in older adults.

Prescribing Cascade

An adverse drug reaction is misinterpreted as a new medical condition, prompting an additional prescription that may itself cause further side effects — a vicious cycle that drives inappropriate polypharmacy.

Anticholinergic Burden

Cumulative anticholinergic effects from multiple medications cause dry mouth, constipation, urinary retention, tachycardia, confusion, and delirium — effects that are dose-additive across the entire regimen.

Time-to-Benefit

Many preventive therapies (e.g., statins, bisphosphonates) require years to confer benefit. In patients with limited life expectancy, the time-to-benefit may exceed the patient's remaining lifespan, shifting the risk-benefit ratio toward discontinuation.

Medication Reconciliation

A structured process of comparing a patient's current medication list against all orders at every transition of care — admission, transfer, and discharge — to identify discrepancies and prevent errors.

✦

KEY TAKEAWAY

Think of an older adult's medication regimen like a loaded backpack on a long hike. Each medication adds weight. A few carefully chosen items (water, map, first-aid kit) are essential for the journey, but unnecessary gear slows you down, increases the risk of injury, and can make the trip miserable. Deprescribing is the process of lightening that backpack — removing items that no longer serve the traveler while keeping the essentials that ensure a safe and comfortable journey.

SECTION 3

Visual Overview — The Prescribing Cascade & Deprescribing Algorithm

The prescribing cascade illustrates how an adverse drug reaction from Drug A is mistaken for a new clinical condition, prompting Drug B, whose own side effects may trigger Drug C. Breaking the cascade requires clinicians to consider whether every new symptom could be medication-related before adding another prescription.

The prescribing cascade is one of the most common and preventable drivers of inappropriate polypharmacy. A classic example involves amlodipine-induced peripheral edema being treated with a loop diuretic, which then causes hypokalemia and volume depletion. The clinician who instead recognizes the edema as a drug side effect can switch to an alternative antihypertensive and avoid a chain of unnecessary prescriptions. On the USMLE, questions about the prescribing cascade typically present a patient who develops a new symptom shortly after a medication was started or dose-adjusted, and the correct answer is to discontinue or substitute the offending agent rather than add another medication.

SECTION 4

Pharmacologic Mechanisms — Age-Related Changes & Drug Interactions

Age-Related Pharmacokinetic Changes

The aging process affects every phase of pharmacokinetics. Absorption is generally preserved with normal aging, though reduced gastric acid production (and widespread use of proton pump inhibitors) can impair absorption of drugs requiring acidic environments, such as ketoconazole and certain iron formulations. Distribution shifts as lean body mass decreases and adipose tissue increases, prolonging the half-life of lipophilic drugs like diazepam (half-life can exceed 100 hours in elderly patients). Decreased serum albumin, particularly in malnourished or acutely ill elderly patients, increases the free fraction of highly protein-bound drugs such as warfarin and phenytoin, enhancing their pharmacologic and toxic effects.

Hepatic metabolism declines primarily through reduced hepatic blood flow and decreased Phase I (CYP450-mediated) reactions; Phase II conjugation is relatively preserved. This distinction is clinically important: benzodiazepines that undergo Phase I metabolism (diazepam, chlordiazepoxide) accumulate to a greater degree in older adults, whereas those requiring only Phase II glucuronidation (lorazepam, oxazepam, temazepam) are preferred. Renal excretion shows the most clinically significant age-related decline, with GFR decreasing approximately 1 mL/min/year after age 40. Renally cleared drugs — digoxin, lithium, aminoglycosides, enoxaparin, metformin, and gabapentin — require dose adjustment based on estimated GFR.

COCKCROFT-GAULT EQUATION

CrCl = [(140 − Age) × Weight (kg)] / [72 × Serum Cr (mg/dL)] (× 0.85 if female)

CrCl = estimated creatinine clearance (mL/min). This formula tends to overestimate GFR in cachectic elderly patients due to low muscle mass producing misleadingly normal serum creatinine values. Always consider functional status alongside calculated values.

Major Drug Interaction Mechanisms

Drug interactions are classified as pharmacokinetic (one drug alters the absorption, distribution, metabolism, or excretion of another) or pharmacodynamic (two drugs produce additive, synergistic, or antagonistic effects at the same or related receptor targets). In geriatric patients, pharmacodynamic interactions are especially dangerous because the aging nervous system is more susceptible to additive sedation, hypotension, QTc prolongation, and bleeding risk. A classic high-yield example is the concurrent use of an SSRI and tramadol, which increases serotonergic activity and can precipitate serotonin syndrome — characterized by altered mental status, autonomic instability, clonus, and hyperthermia.

Interaction Type	Mechanism	High-Yield Example
CYP450 Inhibition	Drug A inhibits CYP enzyme → Drug B accumulates	Fluconazole inhibits CYP2C9 → warfarin toxicity → bleeding
CYP450 Induction	Drug A induces CYP enzyme → Drug B is cleared faster	Rifampin induces CYP3A4 → subtherapeutic warfarin/cyclosporine
Additive Sedation	Two or more CNS depressants produce cumulative sedation	Opioid + benzodiazepine + gabapentin → respiratory depression, falls
QTc Prolongation	Multiple QTc-prolonging drugs increase risk of Torsades de Pointes	Ondansetron + fluoroquinolone + hypokalemia → fatal arrhythmia
Serotonin Syndrome	Additive serotonergic activity from multiple agents	SSRI + tramadol or SSRI + linezolid → clonus, hyperthermia, AMS

Common drug interaction mechanisms tested on USMLE Step 2

SECTION 5

High-Risk Medications in Older Adults — Beers Criteria & Beyond

The American Geriatrics Society (AGS) Beers Criteria is the most widely cited explicit tool for identifying potentially inappropriate medications (PIMs) in adults aged 65 and older. The criteria categorize medications into five lists: (1) PIMs to avoid in most older adults, (2) PIMs to avoid in older adults with specific conditions, (3) drugs to use with caution, (4) drug-drug interactions to avoid, and (5) drugs requiring dose adjustment based on kidney function. Mastery of the highest-yield Beers Criteria categories is essential for USMLE Step 2.

This diagram organizes the most commonly tested Beers Criteria drug classes into six categories. Note that anticholinergics and sedative-hypnotics are the two highest-yield categories because they directly contribute to falls, delirium, and cognitive decline — the most feared geriatric syndromes.

💡

HIGH-YIELD MNEMONIC

For drugs to avoid in older adults with a history of falls, remember "SOAP": Sedative-hypnotics, Opioids, Anticholinergics, and antiPsychotics — each of these increases the risk of orthostatic hypotension, over-sedation, and impaired balance.

SECTION 6

Worked Example — Deprescribing in a Complex Geriatric Patient

Consider the following clinical scenario: Mrs. Johnson is a 82-year-old woman with hypertension, type 2 diabetes, osteoarthritis, insomnia, GERD, and mild Alzheimer's dementia. She was recently admitted after a fall resulting in a hip fracture. Her current medication list includes: amlodipine 10 mg daily, metformin 1000 mg BID, glyburide 5 mg daily, ibuprofen 400 mg TID, zolpidem 10 mg at bedtime, omeprazole 40 mg daily (for 2 years), donepezil 10 mg daily, and diphenhydramine 25 mg at bedtime for sleep. The question asks: which medications should be deprescribed, and how should the process be approached?

Systematic Deprescribing of Mrs. Johnson's Medication List

1
Step 1 — Identify All PIMs Using Beers Criteria

Systematically review each medication against the Beers Criteria. Diphenhydramine is a first-generation antihistamine with strong anticholinergic properties — it worsens cognition in dementia and increases fall risk. Zolpidem is a sedative-hypnotic associated with falls, fractures, and delirium in older adults. Glyburide is a long-acting sulfonylurea with high risk of prolonged hypoglycemia. Ibuprofen (chronic NSAID use) increases GI bleeding, AKI, and exacerbates hypertension.

Four PIMs identified: diphenhydramine, zolpidem, glyburide, ibuprofen
2
Step 2 — Assess the Prescribing Cascade

Consider whether any current medications are treating side effects of other medications. Mrs. Johnson takes diphenhydramine and zolpidem — both for insomnia. Could her insomnia be caused or worsened by donepezil, which commonly causes vivid dreams and sleep disturbance? Also, is the long-standing omeprazole treating true GERD, or was it originally started for NSAID gastroprotection? If the NSAID is discontinued, the omeprazole may no longer be needed.

Potential cascades: insomnia ← donepezil; omeprazole ← NSAID use
3
Step 3 — Prioritize Deprescribing by Harm Potential

The most urgent medications to discontinue are those most likely contributing to her fall and hip fracture. Diphenhydramine should be stopped immediately — it has anticholinergic effects that worsen dementia and increase fall risk. Zolpidem should be tapered and discontinued. Ibuprofen should be stopped and replaced with scheduled acetaminophen for osteoarthritis pain. Glyburide should be switched to a safer alternative (glipizide or consider relaxing HbA1c target in an 82-year-old with dementia).

Priority: Stop diphenhydramine → taper zolpidem → stop ibuprofen → switch glyburide
4
Step 4 — Consider Time-to-Benefit and Goals of Care

Mrs. Johnson has mild Alzheimer's dementia. Donepezil provides modest symptomatic benefit, but as dementia progresses, the benefit diminishes while side effects (GI upset, insomnia, bradycardia) persist. A goals-of-care discussion with the patient and family should explore whether continued donepezil aligns with their priorities. Similarly, with an 82-year-old patient with limited life expectancy, tight glycemic control (HbA1c < 7%) is no longer recommended; the ADA/AGS guideline suggests a target of HbA1c < 8.0−8.5% for patients with complex health, reducing the need for aggressive glucose-lowering agents.

Relax HbA1c target to < 8.0%; discuss continued utility of donepezil
5
Step 5 — Implement Tapering Plan and Monitor

Certain medications require gradual tapering to avoid withdrawal or rebound effects. Omeprazole should be tapered over 2−4 weeks (step down to 20 mg, then to every-other-day dosing) to prevent rebound acid hypersecretion. Zolpidem should be tapered by 50% for 1−2 weeks before discontinuation. After changes, schedule a follow-up within 1−2 weeks to monitor for withdrawal symptoms, rebound conditions, or unmasking of previously suppressed symptoms. Document the rationale for each change.

Net result: 8 medications reduced to 3−4, with substitution of safer alternatives

SECTION 7

Comparing Deprescribing Tools & Screening Criteria

Several validated tools exist for identifying inappropriate prescriptions and guiding deprescribing. Each has distinct strengths and limitations that influence its applicability in different clinical settings. The three most widely referenced tools are the AGS Beers Criteria, the STOPP/START criteria, and the Medication Appropriateness Index (MAI). Understanding their differences helps clinicians select the right approach and is frequently tested on standardized examinations.

Feature	AGS Beers Criteria	STOPP/START	Medication Appropriateness Index
Type	Explicit (list-based)	Explicit (list-based)	Implicit (judgment-based)
Origin	United States (AGS)	Europe (Ireland)	United States
Identifies Omissions	No (PIMs only)	Yes (START criteria)	No
Ease of Use	High — checklist format	Moderate — condition-linked	Low — time-intensive per drug
Patient-Centered	Limited — population-based	Moderate	High — individualized
USMLE Relevance	Very High	Moderate	Low

Comparison of major prescribing appropriateness tools

✦

KEY TAKEAWAY

Beers Criteria are the gold standard for the USMLE but function as a screening tool, not a mandate. Think of the Beers list like a building code inspection checklist — it flags potential safety violations, but the engineer still needs to assess whether each finding is actually dangerous in the specific building's context. Similarly, a Beers-listed medication may be appropriate for a given patient if safer alternatives have failed and the benefit clearly outweighs the risk.

SECTION 8

Advanced Topics — Anticholinergic Burden Scales & Emerging Frameworks

Beyond the Beers Criteria, the concept of cumulative anticholinergic burden has gained prominence as a quantitative approach to measuring drug-related risk. The Anticholinergic Cognitive Burden (ACB) scale assigns each medication a score from 0 to 3 based on its anticholinergic potency: a score of 1 indicates possible anticholinergic activity (e.g., furosemide, metoprolol), 2 indicates definite but mild activity (e.g., cetirizine), and 3 indicates high anticholinergic potency (e.g., oxybutynin, diphenhydramine, paroxetine). The total burden is calculated by summing scores across the entire regimen. An ACB total score ≥ 3 is associated with a clinically meaningful increase in the risk of delirium, cognitive decline, falls, and mortality.

Concept	Current Standard (Step 2 Level)	Emerging / Advanced Framework
PIM Identification	Beers Criteria — explicit drug lists categorized by condition and age	AI-driven clinical decision support integrating genomics, real-time labs, and goals of care
Anticholinergic Risk	ACB scale — summative score of anticholinergic potency	Pharmacogenomic profiling of muscarinic receptor sensitivity and CYP2D6 metabolizer status
Deprescribing	Evidence-based guidelines (PPIs, BZDs, antipsychotics, sulfonylureas)	Shared decision-making tools with patient-facing apps and wearable-generated outcome data
Drug Interactions	Known CYP450 interactions and pharmacodynamic additive effects	Machine-learning models predicting novel interactions from molecular structure databases

Current vs. emerging approaches to medication safety in older adults

The field of geriatric pharmacotherapy is rapidly evolving. Pharmacogenomic testing is beginning to inform prescribing decisions for drugs like clopidogrel (CYP2C19 status), codeine (CYP2D6 ultrarapid metabolizers), and warfarin (CYP2C9/VKORC1). While these applications are not yet standard in geriatric deprescribing, they represent the next frontier of precision prescribing — tailoring medication selection and dosing not just to age and organ function, but to the patient's individual genetic profile. For Step 2, focus on the established tools (Beers, STOPP/START, ACB) and the principle that every medication must justify its place in the regimen at every encounter.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

A 78-year-old man with Parkinson disease and benign prostatic hyperplasia is prescribed oxybutynin for urinary urgency. His daughter calls two days later reporting that he is newly confused and agitated. What is the most likely explanation for his acute change in mental status, and what is the appropriate next step?

Show answer

Oxybutynin is a strongly anticholinergic medication (ACB score 3) that can cause delirium, particularly in patients with pre-existing neurodegenerative disease such as Parkinson disease. The acute confusion is most likely an anticholinergic-induced delirium. The appropriate next step is to immediately discontinue oxybutynin. Patients with Parkinson disease have a depleted cholinergic system, making them exquisitely sensitive to anticholinergic side effects. If urinary urgency still requires treatment, a beta-3 agonist (mirabegron) would be a safer alternative as it lacks anticholinergic activity.

Question 2: BASIC CALCULATION

An 85-year-old, 60 kg woman has a serum creatinine of 1.0 mg/dL. Using the Cockcroft-Gault equation, calculate her estimated creatinine clearance. Should her dose of renally cleared gabapentin (standard dose 300 mg TID) be adjusted?

Show answer

Using the Cockcroft-Gault equation: CrCl = [(140 − 85) × 60] / [72 × 1.0] × 0.85 = [55 × 60] / 72 × 0.85 = [3300 / 72] × 0.85 = 45.8 × 0.85 = 38.9 mL/min. Her estimated CrCl is approximately 39 mL/min, indicating moderate renal impairment (CKD stage 3b). Despite a seemingly normal serum creatinine of 1.0 mg/dL, her low muscle mass masks significant renal dysfunction. Gabapentin requires dose reduction when CrCl is 30−59 mL/min. The appropriate adjusted dose would be 200−300 mg BID rather than TID, with close monitoring for sedation and neurologic side effects.

Question 3: INTERMEDIATE

A 74-year-old woman with atrial fibrillation on warfarin presents with a new diagnosis of a urinary tract infection. She is prescribed trimethoprim-sulfamethoxazole (TMP-SMX). Three days later, her INR is 5.8 (baseline 2.3). What drug interaction explains this finding, and how could it have been prevented?

Show answer

TMP-SMX is a potent inhibitor of CYP2C9, the primary enzyme responsible for S-warfarin metabolism. By blocking CYP2C9, TMP-SMX causes warfarin to accumulate, dramatically increasing the INR and the risk of life-threatening bleeding. This is one of the most common and dangerous pharmacokinetic drug interactions in geriatric practice. Prevention involves either selecting an alternative antibiotic that does not interact with warfarin (such as nitrofurantoin for uncomplicated cystitis, if GFR permits) or, if TMP-SMX is the only appropriate agent, empirically reducing the warfarin dose by 25−50% and checking the INR within 3−5 days of initiating the antibiotic.

Question 4: APPLIED

A 90-year-old nursing home resident with advanced dementia (GDS stage 7), recurrent aspiration pneumonia, and a recent 15-pound weight loss is on the following medications: atorvastatin 40 mg daily, alendronate 70 mg weekly, donepezil 10 mg daily, memantine 10 mg BID, lisinopril 10 mg daily, and aspirin 81 mg daily (primary prevention). Using principles of time-to-benefit and goals of care, which medications should be deprescribed?

Show answer

In a patient with end-stage dementia and limited life expectancy, medications whose time-to-benefit extends beyond the patient's expected survival should be reconsidered. Atorvastatin for primary prevention requires 2−5 years to demonstrate cardiovascular benefit and should be discontinued. Alendronate similarly requires 12−18 months to reduce fracture risk and is challenging to administer properly in a patient with advanced dementia who cannot sit upright for 30 minutes. Aspirin for primary prevention has been shown to cause net harm in older adults and should be stopped. Donepezil and memantine provide minimal benefit in GDS stage 7 dementia and can cause anorexia (worsening weight loss), nausea, and diarrhea; they should be tapered and discontinued. Lisinopril may be continued if the patient has symptomatic heart failure or significant hypertension, but the blood pressure target should be liberalized to avoid hypotension. This approach reduces the regimen from six medications to one or two, aligning with comfort-focused goals of care.

Question 5: CRITICAL THINKING

A hospital implements a quality improvement initiative requiring pharmacists to flag every Beers-listed medication in patients aged 65 and older. After six months, the initiative has reduced Beers medication use by 40%, but patient satisfaction scores have dropped, and readmission rates for pain, insomnia, and anxiety have increased by 12%. Analyze the potential reasons for these unintended consequences, and propose a more nuanced approach to implementing prescribing criteria.

Show answer

This scenario illustrates the critical distinction between appropriate and indiscriminate deprescribing. A blanket policy of removing all Beers-listed medications without considering individual patient context can lead to inadequately treated symptoms. For example, a benzodiazepine that a patient has taken safely for years may be abruptly discontinued, causing rebound anxiety, insomnia, and even withdrawal seizures. Similarly, an NSAID may be the only effective analgesic for a specific patient's arthritis, and removing it without providing adequate alternative pain management leads to suffering and readmission. A more effective approach would integrate Beers screening with individualized clinical assessment — for each flagged medication, the pharmacist and prescriber should conduct a risk-benefit analysis that considers the patient's symptom burden, prior treatment failures, life expectancy, and preferences. Tapering should be gradual with planned follow-up. The initiative should also include START-type screening to ensure that beneficial medications are not being omitted. Quality metrics should track patient-centered outcomes (pain control, sleep quality, functional status) alongside process measures (PIM prevalence), ensuring that the goal remains patient welfare rather than checklist compliance.

SUMMARY

Lesson Summary — Polypharmacy & Medication Safety in Older Adults

Summary

Polypharmacy — defined as the concurrent use of five or more medications — is a leading cause of adverse drug events, falls, delirium, and hospitalizations in older adults. Age-related changes in pharmacokinetics — particularly decreased renal clearance and Phase I hepatic metabolism — and increased pharmacodynamic sensitivity to CNS-active and anticholinergic drugs amplify the risk of drug toxicity. The prescribing cascade — where adverse effects are mistaken for new conditions, prompting additional prescriptions — is a critical mechanism driving inappropriate polypharmacy.

Clinicians use the AGS Beers Criteria and STOPP/START criteria to screen for potentially inappropriate medications, while the deprescribing process involves systematic medication review, assessment of time-to-benefit relative to life expectancy, patient-centered goals-of-care discussions, careful tapering, and structured follow-up. The highest-yield drug classes to avoid include anticholinergics, sedative-hypnotics, long-acting sulfonylureas, chronic NSAIDs, and antipsychotics in dementia. Always remember: Beers Criteria are screening tools, not absolute contraindications — the best prescribing decisions integrate standardized criteria with individualized clinical judgment.